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1. Introduction
Risk prediction is an important component of effective systems of medical care and public
health. Examples of models for risk prediction in current use are the Framingham model1 in
cardiovascular disease and the Gail model2 in breast cancer. Accurate risk prediction enables
clinicians to match the intensity of treatment to the level of risk.3 For many conditions, clinicians
have a limited ability to accurately identify high risk patients, and research efforts continue to be
devoted to improving risk prediction models. In cardiovascular disease, many epidemiological
publications have evaluated whether new predictors can improve the risk predictions from the
Framingham model, which includes the established risk factors age, sex, systolic blood
pressure, lipids and smoking. The goal of such investigations is to evaluate new biomarkers for
the predictive capacity they offer above and beyond established predictors. The improvement in
risk prediction is called the incremental value or prediction increment of the biomarker.
In 2008 Pencina and colleagues4 introduced a new measure of incremental value called the
Net Reclassification Index or NRI. They expanded the definition of the NRI in 2011.5 Variants of
the NRI have recently become very popular in some areas of medical research, especially
cardiovascular epidemiology. There are approximately 800 papers that contain “NRI” and cite
the original4 paper. It is important to understand what such a popular statistic measures and
how it behaves.
Although NRI statistics have become popular, there are common mistakes in interpretation.
Further, since there are now multiple NRIs to choose from, investigators may be unsure which,
if any, to use. In addition, statistical methods pertaining to these indices are not yet welldeveloped. The goals of this review are (i) to clarify the interpretation of NRI statistics; (ii) to
relate NRI statistics to more traditional measures; (iii) to provide guidance on choice of NRI
statistics; (iv) to highlight problems with current methods for calculating confidence intervals and
p-values with NRI statistics; and (v) to recommend methods for NRI confidence intervals.
1.1 NRI and other measures of the prediction increment
This section provides basic definitions and introduces the data on cardiovascular disease risk
that we will use for illustration. Section 2 describes issues with the interpretation and application
of both categorical and category-free NRI statistics. Section 3 describes statistical issues in
applying NRI statistics. Section 4 applies the findings from Sections 2 and 3 to the MESA data.
Section 5 summarizes our review and recommendations.
The context of this article is risk prediction. The specific goal is to improve risk prediction by
adding a new predictor to an existing set of predictors. A traditional way to evaluate the
prediction increment of a new biomarker is to consider the improvement in the area under the
ROC curves for the expanded risk model compared to the risk model without the new predictor.
In other words, one can consider the improvement in AUC (ΔAUC). However, promising new
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markers have failed to produce meaningfully large increases in AUC. 4 There have been
explicit calls to find ways to evaluate new marker other than ΔAUC.6 Responding to these calls,
Pencina and colleagues4 proposed new metrics, IDI and NRI, for quantifying the prediction
increment of a new marker. The NRI statistic has become extremely popular, and is the topic of
this review.
The NRI, as originally proposed, seeks to quantify the effect of a new marker in moving
predictions across clinically meaningful boundaries. In the definition of NRI, the risk prediction
model that uses the established predictors is called the “old” model. The model that adds the
new marker to the established predictors is the “new” model. “Events” are cases — individuals
who have or will have the disease or outcome in the absence of intervention. “Nonevents” are
controls. The formula defining NRI statistics is 4
𝑁𝑅𝐼 = 𝑃(𝑢𝑝|𝑒𝑣𝑒𝑛𝑡) − 𝑃(𝑑𝑜𝑤𝑛|𝑒𝑣𝑒𝑛𝑡) + 𝑃(𝑑𝑜𝑤𝑛|𝑛𝑜𝑛𝑒𝑣𝑒𝑛𝑡) − 𝑃(𝑢𝑝|𝑛𝑜𝑛𝑒𝑣𝑒𝑛𝑡)

(1)

“Up” means that the new risk model places an individual into a higher risk category than the old
model. Similarly, “down” means the new model places an individual into a lower risk category.
For example, NRI0.2 means a two-category NRI with cut-off at 0.20 defining low and high risk.
NRI0.1,0.2 is a three-category NRI with cut-offs at 0.10 and 0.20 defining low, medium, and high
risk categories. Any set of risk thresholds can be used to define an NRI statistic.
The definition of the NRI in expression (1), which was originally based on discrete pre-defined
risk categories, generalizes to any upward or downward movement in predicted risks.5 The
“category-free NRI” (also called “continuous NRI”) interprets (1) this way. We use NRI>0 to
denote the category-free NRI.
The idea behind the NRI is that a valuable new biomarker will tend to increase predicted risks or
risk categories for events; and decrease predicted risks or risk categories for nonevents.
P(up|event) and P(down|nonevent) form the positive components of the NRI in expression (1).
On the other hand, events that move down and nonevents that move up are mistakes
introduced by the new marker — these are the negative components of (1).
An NRI statistic is the sum of the “event NRI” and the “nonevent NRI”:
𝑁𝑅𝐼𝑒 = 𝑃(𝑢𝑝|𝑒𝑣𝑒𝑛𝑡) − 𝑃(𝑑𝑜𝑤𝑛|𝑒𝑣𝑒𝑛𝑡)
𝑁𝑅𝐼𝑛𝑒 = 𝑃(𝑑𝑜𝑤𝑛|𝑛𝑜𝑛𝑒𝑣𝑒𝑛𝑡) − 𝑃(𝑢𝑝|𝑛𝑜𝑛𝑒𝑣𝑒𝑛𝑡)

(2)
(3)

0.2
>0
For example, 𝑁𝑅𝐼 0.2 = 𝑁𝑅𝐼𝑒0.2 + 𝑁𝑅𝐼𝑛𝑒
and 𝑁𝑅𝐼 >0 = 𝑁𝑅𝐼𝑒>0 + 𝑁𝑅𝐼𝑛𝑒
.

For the two-category setting, Pencina et al.5 generalized the NRI to consider the savings s1 from
identifying an event as high risk and s2 from identifying a nonevent as low risk. s1 is meant to
capture the adverse events that are avoided by labeling a person destined to have an event as
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high risk. s2 should capture all the savings (adverse events, money) from allowing a nonevent
to avoid unnecessary treatment. The “weighted NRI,” wNRI, is the average savings per person.
𝑤𝑁𝑅𝐼 = 𝑠1 �𝑃(𝑒𝑣𝑒𝑛𝑡|𝑢𝑝)𝑃(𝑢𝑝) − 𝑃(𝑒𝑣𝑒𝑛𝑡|𝑑𝑜𝑤𝑛)𝑃(𝑑𝑜𝑤𝑛)�
+𝑠2 (𝑃(𝑛𝑜𝑛𝑒𝑣𝑒𝑛𝑡|𝑑𝑜𝑤𝑛)𝑃(𝑑𝑜𝑤𝑛) − 𝑃(𝑛𝑜𝑛𝑒𝑣𝑒𝑛𝑡|𝑢𝑝)𝑃(𝑢𝑝))

(4)

In this review we refer to two other measures of the prediction increment, ΔAUC (mentioned
above) and ΔNB. The metric ΔNB refers to the change in Net Benefit associated with the use of
the new marker.7 For example, if the risk model is used to classify individuals as “high risk” or
“low risk” and high risk entails an intervention, the Net Benefit is
𝑁𝐵 = 𝐵 ⋅ 𝑃(𝑒𝑣𝑒𝑛𝑡)𝑃(ℎ𝑖𝑔ℎ|𝑒𝑣𝑒𝑛𝑡) − 𝐶 ⋅ 𝑃(𝑛𝑜𝑛𝑒𝑣𝑒𝑛𝑡)𝑃(ℎ𝑖𝑔ℎ|𝑛𝑜𝑛𝑒𝑣𝑒𝑛𝑡)

(5)

where B is the average benefit of the intervention among those who otherwise would have an
event and C is the cost of intervention (including side effects) to nonevents. For old and new risk
models, the change in Net Benefit, ΔNB, is a measure of the prediction increment of the new
marker.
1.2 Example: Coronary Artery Calcification and Predicting Coronary Events
Polonsky et al.8 examined the prediction increment of the coronary artery calcium score (CACS)
for predicting coronary heart disease (CHD) among 5878 participants in the Multi-Ethnic Study
of Atherosclerosis (MESA). Median follow-up was 5.8 years and 209 CHD events were
observed. The cohort was 54% female, and the mean age was 62 years with a standard
deviation of 10 years. The “old” risk model included the risk factors from the Framingham risk
model and race; the “new” model added CACS. We will use these data to illustrate metrics and
methods. We estimate risks using Cox models; for simplicity we otherwise ignore censoring in
the data, following Polonsky et al.8 We refer readers to the original paper8 for more details.
2. Interpreting NRI
2.1 NRI is not a proportion
A common mistake is to interpret the NRI as a proportion.9 For example, it is incorrect to
interpret the NRI as “the proportion of patients reclassified to a more appropriate risk
category.”10 That is P(up and event)+P(down and nonevent). The NRI combines four
proportions but is not a proportion itself.9 In particular, the maximum value of the NRI is 2.
NRIe and NRIne are easier to interpret than NRI because they are differences in proportions.
NRIe is the net proportion of events assigned a higher risk or risk category. NRIne is the net
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proportion of nonevents assigned a lower risk or risk category. The word “net” here is crucial for
correct interpretation.
2.2 Issues with combining event and nonevent NRIs
Given the interpretations of NRIe and NRIne, it is not clear why one would want to take a simple
sum (or unweighted average) to produce the NRI. One logical alternative is to weight by the
prevalence of events. This weighting extends the interpretations of NRIe and NRIne to the whole
population. We define the “population-weighted NRI” as ρNRIe +(1–ρ)NRIne, where ρ is the
prevalence of the condition. The population-weighted NRI can be interpreted as the net change
in the proportion of subjects assigned a more appropriate risk or risk category under the new
model.
The MESA data illustrate another problem with the unweighted sum of NRIe and NRIne. Using 5year risks, NRI0.1=0.164. Looking at the components we see that NRIe0.1=0.191 but the nonevent
0.1
= –0.027. Among nonevents, CACS introduces many more errors than
NRI is negative, NRIne
corrections at the 10% risk threshold. Since there are many more nonevents than events (a
common situation), the new risk model introduces many more errors than corrections overall.
The positive value for NRI0.1 masks the population-level results. Estimating the prevalence with
3.6%, the population-weighted NRI0.1 is –0.020. That is, the net proportion of subjects assigned
to a more appropriate risk category using the 0.1 threshold is –0.02.
The population-weighted NRI illustrates one problem with the NRI. However, we do not
advocate its use because there is no compelling advantage in collapsing NRIe and NRIne into a
single number. NRIe and NRIne tell us how the new risk model (potentially) improves prediction
for events and, separately, for nonevents. The two types of improvements have different
implications. Important information is lost when these two summaries are combined. 11
2.3 Large and small values for NRI>0 are undefined
Ideally, a measure of incremental value has an interpretation in terms of the clinical or public
health benefit of incorporating the new marker. Pencina et al.12 remark that “further research is
needed to determine meaningful or sufficient degree of improvement” in NRI>0”. NRI>0 has no
interpretation that translates to the clinical benefit of the new marker.13 If it did, then the
magnitude of the index would be directly applicable and a marker's sufficiency for improving
prediction would be apparent. Other metrics, including ΔAUC, share the problem of lacking a
clinically meaningful interpretation. However, an additional problem with NRI>0 is that its scale is
unfamiliar.
Pencina et al.12 give a mathematical example of a new marker described as having “strong
effect size.” Supplement C describes the structure of the data considered by Pencina et al.12
Here and throughout this review, X represents the established predictor or set of predictors, and
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Y is the candidate new predictor. In the example,12 the new marker Y yields NRI>0 =0.622. Is
0.622 large? Consider Figures 1 and 2. In all four examples in the figures, Y has the same
distribution, and the odds ratio for Y given the baseline marker X is constant. The four
examples differ only in the strength of the old risk model, i.e., the predictive capacity of X. At
one extreme, the old risk model is useless, with AUC=0.5. At the other extreme, the old risk
model is excellent with AUC=0.99. The figures suggest that the prediction increment forY
diminishes as the strength of the old model increases. Yet NRI>0=0.622 in all four cases.
Clearly there are important aspects of prediction not captured by NRI>0.12
2.4 NRI>0 does not contrast the performance of the new risk model with the performance
of the old risk model
Most measures of incremental value are constructed by summarizing the performance of the old
risk model, summarizing the performance of the new risk model, and comparing the two
summaries. ΔAUC and ΔNB are two examples. NRI>0 is fundamentally different. It is not a
difference of two performance measures for the two risk models. Instead, for each individual it
compares the old and new risk values. However, within-individual changes in risk do not
necessarily translate into improved performance on a population level. For example, Figure 2
(bottom row) shows examples where there are lots of changes in individual predicted risks
(NRI>0=0.622), but the distribution of predicted risks in the population remains almost exactly the
same.
When assessing a new biomarker, ultimately we want to know whether clinicians should
continue using the old risk model or switch to the new, expanded risk model. To answer this
question we need to assess the performances of each of the risk models and compare them.
NRI>0 measures the difference between the old and new risk models within individuals without
teaching us about the performances of the models.
2.5 NRI>0 incorporates irrelevant information
NRI>0 , like ΔAUC, does not rely on risk thresholds. Greenland14 points out that “cutpoint free”
indices incorporate irrelevant information, diminishing their potential for clinical relevance. For
example, AUC summarizes the entire ROC curve, including parts of the curve describing
sensitivity for unacceptably poor specificity. There are two ways in which NRI>0 incorporates
irrelevant information. First, NRI>0 does not account for the size of changes in a predicted risk.
Infinitesimally small changes “count” even though they are clinically irrelevant. Second, NRI>0
does not account for an individual's position on the risk distribution. An event at the high end of
the risk distribution who moves to an even higher risk reflects positively on NRI>0. Such
movement likely has little effect on treatment decisions. A new marker is beneficial if it improves
treatment decisions, which often means the marker can discriminate between events and
nonevents in the middle of the risk distribution.
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>0
For the MESA data, NRIe>0=0.378 and NRIne
=0.319. 20.6% of events have a new 5-year risk
within 1% of the old risk. Among non-events the proportion is 52.8%. Therefore, a sizeable
>0
are small, likely
proportion of changes summarized by NRIe>0 and especially by NRIne
inconsequential changes.

2.6 NRI>0 can make uninformative new markers appear predictive
Hilden and Gerds15 and Pepe and colleagues16 report a problematic feature of NRI>0. Suppose
an old risk model (risk(X)) and a new risk model (risk(X,Y)) are fit to a training dataset. Suppose
further that the new marker Y is completely uninformative. To avoid the optimistic bias caused
by using the same data to fit and evaluate model performance, a standard strategy is to use an
independent dataset to assess the models’ performances. However, NRI>0 tends to be positive
for uninformative Y, even when NRI>0 is computed on a large, independent validation dataset
that was not used to fit the models.16 This problem is likely to arise in settings where the risk
models are not well calibrated, a common phenomenon in practice. In contrast to NRI>0, more
standard measures such as ΔAUC do not suffer this problem. These results show that NRI>0
can mislead researchers to believe that an uninformative marker improves prediction.
2.7 For 3+ categories NRI weights reclassifications indiscriminately
The purpose of risk categorization is to guide appropriate treatment decisions. For
cardiovascular disease, suppose low risk indicates no intervention, medium risk indicates
lifestyle changes, and high risk indicates both lifestyle changes and pharmaceutical intervention.
When categories correspond to treatment decisions, the nature of reclassification matters, not
just the direction. For example, an event whose risk category changes from high risk to low risk
is a more serious error than an event moving from high risk to medium risk.
When there are three or more risk categories, one should consider all the ways a new
biomarker can move individuals among risk categories. For three risk categories there are three
ways of moving “up”: low risk to medium risk; medium to high; and low to high. The 3-category
NRIe gives each of these equal weight; in particular, moving up two risk categories counts the
same as moving up one. Supplement B describes how an appropriate weighting could be
incorporated into a statistic. Weighting the different types of reclassification is extremely
challenging, but that challenge does not justify using equal weights. As an alternative to
assigning weights and providing a single numerical summary, one can instead examine the
different types of reclassification in a reclassification table (e.g., Table 2).
Polonsky et al.8 considered 3-category NRIs with thresholds at 0.03 and 0.1 defining low,
medium, and high 5-year risk. NRI0.03, 0.1=0.25. The value is driven by events (NRIe0.03,0.1 =0.225
0.03,0.1
and NRIne
=0.023), even though most of the population are nonevents. NRI0.03, 0.1=0.25 is a
very coarse summary and almost impossible to interpret (see 2.2). Table 1 shows that the new
risk model tends to place nonevents in the low and high risk categories, placing fewer
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nonevents in the medium risk category than the old risk model. If the harm of moving a
nonevent from medium risk to high risk is greater than the benefit of moving a nonevent from
medium risk to low risk, then the harms of the new risk model outweigh the benefits among
0.03,0.1
nonevents. The single numerical summary, NRIne
=0.023, does not reflect this.

Table 2 shows the reclassifications of nonevents and, separately, events between the old and
new risk models in the MESA data. Such tables are interesting and potentially instructive.
However, it is easiest and most informative to simply look at how a risk model assigns
nonevents and events to risk categories. This information appears on the margins of Table 2,
and more succinctly in Table 1. NRI statistics do not capture this important information.
2.8 2-category NRIs: new names for existing measures

When there are two risk categories, low and high, NRIe is the change in the proportion of events
assigned to the high risk category, i.e., the change in the True Positive Rate ( ΔTPR). NRIne is
the change in the proportion of nonevents designated low risk. In other words, NRIne = –ΔFPR,
where ΔFPR is the change in the False Positive Rate. For 2 risk categories, the populationweighted NRI (Section 2.2) is the change in the misclassification rate.
Furthermore, wNRI is the same as the change in Net Benefit between the old and new risk
models (Supplement A or Van Calster et al17). In other words, wNRI=ΔNB.
3. Data Analysis with NRI
Common practice is as follows. Investigators have a dataset that includes established risk
factors (X) for a condition of interest and a potentially useful new marker (Y). They fit two
regression models: an “old” model that uses only X, and a “new” model that uses both X and Y.
The risk models are typically logistic regression models, or Cox models if data are censored.
The prediction increment of Y is then assessed, typically using the same data that were used to
fit the models.
3.1 NRI should not be used for testing
A researcher may consider testing the null hypothesis H0 : NRI=0. Pencina et al.4 provide a zstatistic for NRI-based testing. However, the test based on this z-statistic has never been
validated. Section 3.2 and Supplements D and E discuss problems with the variance formula
that this z-statistic is based on.18
Interestingly for the category-free NRI, NRI>0, hypothesis testing is unnecessary. Pepe et al.19
show that rejecting the null hypothesis H0 : NRI>0=0 is implied by rejecting the null hypothesis
about the novel marker being a risk factor. In other words, once a test on the coefficient of the
new marker is performed, it is redundant to perform a test based on NRI>0.
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t
For the two-category NRIet or NRIne
where t is the risk threshold, one cannot reject H0 : NRIet = 0
t
= 0 on the basis of Y being a risk factor. Good tests are not yet established for
and H0 : NRIne
these null hypotheses.

We favor inference about the nature and size of the prediction increment rather than testing a
null hypothesis of no improvement. Such inference is challenging. At the early stages of model
development it might be unclear how a risk model will be used, yet understanding how a risk
model will be used is important for appropriately evaluating incremental value. Setting aside
these larger considerations, the next section considers methods for constructing confidence
intervals for NRI statistics.
3.2 NRI Confidence Intervals
We conducted a simulation study to evaluate methods for constructed NRI confidence intervals.
Based on Section 2, we only considered category-free and 2-category event and non-event NRI
statistics. Results indicate that the most reliable confidence intervals use a bootstrap estimate
of the variance of the statistic. Such confidence intervals outperformed confidence intervals
�1 proposed by Pencina et al.4 and other types of bootstrap
constructed using the estimator V
confidence intervals. Supplements C and D describe the simulation study and its results in
detail.
4. NRI inference in the MESA data
In the MESA data, we used 5-year risk thresholds 0.03 and 0.1 following Polonsky et al.8 Table
3 compares confidence intervals for category-free and various 2-category event and nonevent
NRIs. Confidence intervals computed with bootstrapping are usually, but not always, wider than
confidence intervals computed using V�1 . For the 2-category NRIs with threshold 0.03 for 5-year
risk, the changes in the true and false positive rates are modest, with an estimated 5.5%
reduction in the false positive rate and 2.9% increase in the true positive rate. For the 0.1 risk
threshold, adding CACS to risk prediction increases the true positive rate substantially (19.1%),
but also increases the false positive rate by 2.7%.
Although the reclassification table (Table 2) and summary statistics (Table 3) are interesting, we
find the risk distributions (Table 1) most useful. Table 1 shows that adding CACS to prediction
increases the proportion of events labeled as high risk. Unfortunately, it also increases the
proportion of nonevents labeled as high risk. Since nonevents vastly outnumber events, Table 1
identifies an important problem with adding CACS to the risk model.
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5. Discussion and Summary
The recent literature on measures of incremental value developed as follows. Dissatisfaction
with ΔAUC led to proposals for measures based on risk categories and reclassification.20 The
category-based NRI soon followed to address issues with those new measures.4 A preference
to avoid arbitrary or weakly-justified risk thresholds led to the proposal for NRI>0.5 Unfortunately,
NRI>0 has many of the same problems as ΔAUC. Neither measure is clinically meaningful, both
measures are broad summaries of changes in risk models, and both measures incorporate
irrelevant information. In these respects, things have come full circle. It is difficult to understand
whether a value of NRI>0 is large or small, and this is only partly due to lack of experience with
the index. Furthermore, without proper attention to model fit, NRI>0 can mislead researchers to
believe that an uninformative marker improves prediction.15-16 We are skeptical that NRI>0 will
help investigators develop biomarkers or improve risk models, and are concerned about the
potential for NRI>0 to mislead.
The NRI statistics that are most useful are re-named versions of existing measures. Specifically,
(1) event and nonevent 2-category NRIs are the changes in the true and false positive rates;
and (2) the weighted 2-category NRI is the change in Net Benefit. In both cases, we prefer the
established, descriptive terminology.
We recommend the bootstrap for estimating the variance of NRI estimates and constructing
confidence intervals. However, methodology that works well for markers with small prediction
increment is needed.21
The issues described in Sections 2.3 and 2.4 for NRI>0 also apply to NRIs for 3+ categories.
However, the overriding issues with NRIs for 3+ categories is that they do not discriminate
between different types of reclassification — all upward movements in risk categories count the
same, as do all downward movements. We thus recommend against NRI statistics for 3 or
more categories. As in the 2-category case, if the benefits and costs of different types of
classification can be specified, these can be used as weights in a weighted NRI, which would be
the same as the change in net benefit. This is a challenging approach and, to the best of our
knowledge, has not yet been done in practice. A practical alternative is to examine how the old
and new risk models place events and nonevents into the risk categories (e.g. Table 1). A
reclassification table (e.g. Table 2) may also be interesting as it informs about classification
achieved with the new marker within strata defined by the baseline risk model. Depending on
the application, select 2-category summary statistics may be appropriate, particularly for risk
thresholds that indicate expensive or invasive treatment.
NRI>0 should not be used in hypothesis testing. Better tests are available and validated for the
regression setting. However, we emphasize the limited value of hypothesis testing in assessing
biomarkers. We recommend that investigators focus on describing the operating characteristics
of risk models. Ideally, then, the prediction increment of a new marker is described in terms of
how it improves risk model operating characteristics.
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Figures
Figure 1. In each plot the solid black line is the ROC curve for the “old” marker and the dotted
blue line is the ROC curve for the “new” risk model that incorporates the new marker. The new
marker has identical distribution in all four cases. NRI>0=0.622 in all cases, despite the fact that
the prediction increment of the new marker decreases as the strength of the old model
increases.
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Figure 2: The same data as Figure 1 are shown here in terms of the distributions of risks for old
and new risk models. Risks are shown on the log odds scale. Blue curves are the risks using
the established predictors X and red curves are risks using X as well as the new marker Y.
Dotted lines are nonevents and solid lines are events.
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Tables
Table 1. Proportions of subjects in low, medium, and high risk categories in the MESA data,
presented separately for events (those with coronary heart disease) and nonevent (those
without coronary heart disease).
Risk

Old risk model

New risk model (model with CACS)

Category

nonevent

event

nonevent

event

0-3%

67.1%

27.3%

70.6%

24.4%

3–10%

30.6%

55.0%

22.3%

38.8%

>10%

4.4%

17.7%

7.1%

36.8%

Total

5669

209

5669

209

100%

100%

100%

100%
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Table 2: Reclassification table for nonevents and events in the MESA data. Each interior cell
contains the number of individuals in the corresponding risk categories under the old and new
risk models. The percentages in interior cells are among nonevents or events. The rows and
columns labeled “Total” show the distributions of nonevents and events into the three risk
categories under the old and new risk models – the same data are found in Table 1

Old
Model
0–3%

3–10%

>10%

Total

Old
Model
0–3%

3–10%

>10%

Total

0-3%

Nonevents
Model with CACS
3-10%

>10%

58%

7%

1%

3276

408

5

12%

14%

4%

697

791

244

1%

1%

3%

30

63

155

4%

71%

22%

7%

5669

0-3%

Events
Model with CACS
3-10%

>10%

Total

16%

11%

0%

34

22

1

7%

25%

23%

15

52

48

1%

3%

13%

2

7

28

18%

24%

39%

37%

209

Total

65%

31%

27%

55%
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Table 3: Confidence Intervals for select event and nonevent NRIs in the MESA data. Intervals
based on bootstrap estimates of the standard error, which we recommend, tend to be wider
than intervals based on the formula for the variance of the estimated NRI statistic.. Recall that
𝑡
for a threshold t delineating high risk, 𝑁𝑅𝐼𝑒𝑡 = ΔTPR and 𝑁𝑅𝐼𝑛𝑒
= –ΔFPR.

formula
bootstrap

formula
bootstrap

formula
bootstrap

𝑁𝑅𝐼𝑒>0 = 0.378

>0
𝑁𝑅𝐼𝑛𝑒
= 0.319

(0.275,0.481)

(0.257,0.382)

𝑁𝑅𝐼𝑒0.03 = 0.029

0.03
𝑁𝑅𝐼𝑛𝑒
= 0.055

(–0.039,0.097)

(0.026,0.084)

𝑁𝑅𝐼𝑒0.1 = 0.191

0.1
𝑁𝑅𝐼𝑛𝑒
= 0.027

(0.252,0.503)

(–0.030,0.088)

(0.294,0.344)

(0.044,0.067)

(0.125,0.258)

(–0.034,–0.021)

(0.097,0.286)

(–0.039,–0.016)

http://biostats.bepress.com/uwbiostat/paper393

SUPPLEMENTARY ONLINE MATERIAL
Net Reclassification Indices for Evaluating Risk Prediction
Instruments: A Critical Review
Kathleen F. Kerr, Zheyu Wang, Holly Janes,
Robyn L. McClelland, Bruce M. Psaty, Margaret S. Pepe
July 10, 2013

1

Hosted by The Berkeley Electronic Press

A

2-category N RI and Net Benefit

For a single risk model, let B to be the beneﬁt of identifying an event as high risk and C as the cost
of identifying a nonevent as high risk. Deﬁne the Net Beneﬁt (3) of a risk model as
N B = B · P (event)P (high|event) − C · P (nonevent)P (high|nonevent).

(1)

Now, suppose we have “old” and ”new” risk models, where the new model adds an additional marker
to the old model. It is natural to quantify the incremental value of the new marker as ∆N B, the
change in the Net Beneﬁt by using the new marker for prediction. Let highn and higho denote that
a subject is in the high risk category according to the new and old risk models, respectively. Then
∆N B = B · P (event)[P (highn |event) − P (higho |event)]
−C · P (nonevent)[P (highn |nonevent) − P (higho |nonevent)].

(2)

For any individual, considering the old and new risk models there are four cases: the individual can
be classiﬁed low risk by both models, high risk by both models, low and then high, or high and then
low. Let ll, hh, lh, hl denote these four cases, where the ﬁrst position is for the old risk model and the
second position is for the new risk model. Then we can write the ﬁrst line of (2) as
B · P (event)[P (hh|event) + P (lh|event) − P (hh|event) − P (hl|event)]
= B · P (event)[P (lh|event) − P (hl|event)]
= B · P (event)[P (up|event) − P (down|event)]

(3)

Similarly, the second line of (2) can be written
−C · P (nonevent)[P (up|nonevent) − P (down|nonevent)].

(4)

∆N B = B · P (event)[P (up|event) − P (down|event)]
−C · P (nonevent)[P (up|nonevent) − P (down|nonevent)]
P (event|up)P (up) P (event|down)P (down)
= B · P (event)[
−
]
P (event)
P (event)
P (nonevent|up)P (up) P (nonevent|down)P (down)
−C · P (nonevent)[
−
]
P (nonevent)
P (nonevent)
= B[P (event|up)P (up) − P (event|down)P (down)]
−C[P (nonevent|up)P (up) − P (nonevent|down)P (down)]

(5)

Therefore,

Thus the wN RI is exactly the change in the Net Beneﬁt for the old and new risk models.

2
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B

3-category N RI and Net Benefit

First, we generalize the deﬁnition of the 3-category NRI by considering the diﬀerent ways individuals
can move between risk categories. Second, we deﬁne Net Beneﬁt for a risk model when there are three
categories and derive ∆N B for the prediction increment. Last, we derive wN RI for the 3-category
N RI similar to the derivation of the wN RI for two-categories in Pencina et al. (4). We we show that
wN RI for three categories is the same as ∆N B, just as they are equal for two categories.

B.1

Generalized N RI for 3 categories

The deﬁnition of the N RI is
N RI = P (up|event) − P (down|event) + P (down|nonevent) − P (up|nonevent).

(6)

For three categories, “up” can mean three things: move from low to medium, from medium to high,
or from low to high. Let l, m, and h represent the low, medium, and high categories. For 3 categories
we can write the N RI as

−
+
−
=
−
+
−

P (lm|event) + P (lh|event) + P (mh|event)
P (ml|event) − P (hl|event) − P (hm|event)
P (ml|nonev) + P (hl|nonev) + P (hm|nonev)
P (lm|nonev) + P (lh|nonev) + P (mh|nonev)
[P (event|lm)P (lm) + P (event|lh)P (lh) + P (event|mh)P (mh)]/P (event)
[P (event|ml)P (ml) + P (event|hl)P (hl) + P (event|hm)P (hm)]/P (event)
[P (nonev|ml)P (ml) + P (nonev|hl)P (hl) + P (nonev|hm)P (hm)]/P (nonev)
[P (nonev|lm)P (lm) + P (nonev|lh)P (lh) + P (nonev|mh)P (mh)]/P (nonev)

(7)

(8)

This is a linear combination of P (event|∗)P (∗) and P (nonev|∗)P (∗) where ∗ represents movement
between risk categories.

B.2

Net Benefit and Three categories

Let Bh and Bm be the beneﬁts for assigning a case to the high and medium risk categories, respectively.
Let Ch and Cm be the costs for assigning a control to the high and medium risk categories, respectively.
Then the Net Beneﬁt or a risk model is
N B = Bh P (h|event)P (event) + Bm P (m|event)P (event)
− Ch P (h|nonev)P (nonev) − Cm P (m|nonev)P (nonev).
Use the subscript n and o for the new and old risk models, respectively. Then
∆N B =
+
−
−

Bh P (event)[P (hn |event) − P (ho |event)]
Bm P (event)[P (mn |event) − P (mo |event)]
Ch P (nonev)[P (hn |nonev) − P (ho |nonev)]
Cm P (nonev)[P (mn |nonev) − P (mo |nonev)]

(9)
(10)
(11)
(12)

3
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events

nonevents
high
high
shm

smh

Shm+Sml

medium

Slm+Smh
slm

sml
low

Figure 1: Parameters for the derivation of wNRI for 3 risk categories.
Now, P (hn ) = P (lh) + P (mh) + P (hh) and P (ho ) = P (hl) + P (hm) + P (hh), so P (hn ) − P (ho ) =
P (lh) + P (mh) − P (hl) − P (hm). The same holds when conditioning on event status and the same
reasoning can be applied to P (mn ) − P (mo ). Applying this reasoning and Bayes’ rule gives the
following expression for the change in Net Beneﬁt for using the new risk model instead of the old risk
model:
∆N B =
+
−
−

B.3

Bh [P (event|lh)P (lh) + P (event|mh)P (mh) − P (event|hl)P (hl) − P (event|hm)P (hm)]
Bm [P (event|lm)P (lm) + P (event|hm)P (hm) − P (event|ml)P (ml) − P (event|mh)P (mh)]
Ch [P (nonev|lh)P (lh) + P (nonev|mh)P (mh) − P (nonev|hl)P (hl) − P (nonev|hm)P (hm)]
Cm [P (nonev|lm)P (lm) + P (nonev|hm)P (hm) − P (nonev|ml)P (ml) − P (nonev|mh)P (mh)].

wNRI derived for three categories

Following Pencina et al. (4), let slm be the savings for re-classifying an event from low risk to medium
risk and smh be the savings for re-classifying an event from medium risk to high risk. The savings
from re-classifying an event from low risk to high risk is then slm + smh . Similarly, for nonevents we
use parameters shm and sml . The total savings using the new risk model instead of the old risk model
is
nmh [P (event|mh)smh − P (nonev|mh)shm ] +
nlm [P (event|lm)slm − P (nonev|lm)sml ] +
nlh [P (event|lh)(smh + slm ) − P (nonev|lh)(shm + sml )] +
nhm [−P (event|hm)smh + P (nonev|hm)shm ] +
nml [−P (event|ml)slm + P (nonev|ml)sml ] +
nhl [−P (event|hl)(smh + slm ) + nlh P (nonev|lh)(shm + sml )]

4
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Divide through by n so that nmh /n = P (mh) and so forth. Then the expected savings for use of the
new risk model:
smh [P (event|mh)P (mh) + P (event|lh)P (lh) − P (event|hm)P (hm) − P (event|hl)P (hl)]
+ slm [P (event|lm)P (lm) + P (event|lh)P (lh) − P (event|ml)P (ml) − P (event|hl)P (hl)]
+ shm [P (nonev|hm)P (hm) + P (nonev|hl)P (hl) − P (nonev|mh)P (mh) − P (nonev|lh)P (lh)]
+ sml [P (nonev|ml)P (ml) + P (nonev|hl)P (hl) − P (nonev|lm)P (lm) − P (nonev|lh)P (lh)]
Compare this expected savings with expression (8) for the generalized deﬁnition of the 3-category
NRI. The expected savings can be viewed as a diﬀerently-weighted linear combination of P (event|∗)P (∗)
and P (nonev|∗)P (∗) where ∗ represents movement between risk categories.
Now return to the expression for ∆N B and reparametrize: replace Bm with slm and Bh with
slm + smh . Then from the ﬁrst two lines we get:
slm [P (event|lh)P (lh) + P (event|lm)P (lm) − P (event|hl)P (hl) − P (event|ml)P (ml)]
+ smh [P (event|lh)P (lh) + P (event|mh)P (mh) − P (event|hl)P (hl) − P (event|hm)P (hm)]
= slm P (event)[P (lh|event) + P (lm|event) − P (hl|event) − P (ml|event)]
+ smh P (event)[P (lh|event) + P (mh|event) − P (hl|event) − P (hm|event)]
For the second two lines replace Cm with sml and Ch with shm + sml . The last two lines of ∆N B are:
sml [P (nonev|hl)P (hl) + P (nonev|ml)P (ml) − P (nonev|lh)P (lh) − P (nonev|lm)P (lm)]
+ shm [P (nonev|hl)P (hl) + P (nonev|hm)P (hm) − P (nonev|lh)P (lh) − P (nonev|mh)P (mh)]
= sml P (nonev)[P (hl|nonev) + P (ml|nonev) − P (lh|nonev) − P (ln|nonev)]
+ shm P (nonev)[P (ml|nonev) + P (mh|nonev) − P (lm|nonev) + P (hm|nonev)]

5
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C

Simulation Study: Methods

Our primary simulation model is Binormal Equal Correlation data (5). Let ρ denote disease prevalence. The old marker X and the new marker Y are bivariate Normal in both events and nonevents.
(
)
(( 0 ) ( 1 r ))
X
D = 0 ∼ N2
,
Y
0
r 1
(
)
(( µ ) ( 1 r ))
X
X
D = 1 ∼ N2
,
Y
µY
r 1
A feature of this model is that the logistic model holds for both P (D = 1|X = x, Y = y) and
P (D = 1|X = x).
µ2
ρ
− x + µx x
1−ρ
2
µX − rµY
µY − rµX
ρ
µ2X + µ2Y − 2rµX µY
logitP (D = 1|X = x, Y = y) =
x
+
y
+
log
−
.
1 − r2
1 − r2
1−ρ
2(1 − r2 )
logitP (D = 1|X = x) = log

Therefore, when we apply logistic regression with data simulated from this model the risk model is
correctly speciﬁed.
Note that µX and µY summarize the marginal predictive abilities of X and Y respectively. r is the
conditional correlation between the markers – conditional on disease status. Throughout this paper
X represents the established marker(s) and Y represents the new predictor. The incremental value
of Y depends not just on µY but also on r and µX . In general the incremental value of Y is not a
monotone function of µY when r ̸= 0 (2).
A convenient feature of this model is that there is a simple formula for N RI >0 :
√
2
2
( MX,Y − MX )
1
>0
>0
>0
N RIe = N RIne = N RI = 2Φ
− 1.
2
2
2
where MX,Y
is the squared Mahalanobis distance between events and nonevents in the distribution of
(X, Y ) and MX2 is the squared Mahalanobis distance between events and nonevents in the distribution
of X. Φ is the distribution function of a standard Normal random variable. Any choice of simulation
parameters, µX , µY , and r exactly determine N RI >0 . When we consider the two-category N RI we use
consider N RI 0.1 . We calculated true values for N RI 0.1 by simulating datasets of size 5,000,000 and
ﬁtting the logistic models to get very precise estimates of the proportion of subjects with predicted
risks above and below the high-risk threshold.

6
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D

Confidence intervals for N RI

Investigators seek to understand the nature of the improvement in risk prediction oﬀered by a marker.
To that end, it is of interest to estimate summaries of the prediction increment, and to quantify the
uncertainty of those estimates using conﬁdence intervals. For example, researchers routinely provide
estimates and conﬁdence intervals for the change in the area under the ROC curve, ∆AU C.
Many researchers are familiar with constructing conﬁdence intervals for a parameter using the
point estimate for the statistic and an estimate of its standard error: a 95% conﬁdence interval for
c θ̂). There are three requirements for a conﬁdence interval
a parameter θ is formed as θ̂ ± 1.96 · SE(
constructed in this way to have the proper coverage: the estimate must be (1) consistent, which means
that it estimates the true value in large samples; (2) have a Normal sampling distribution; and (3)
c must be a consistent estimate of the standard error of the estimate.
SE
[
Pencina et al. (4) provide a formula for estimating V1 , the variance
√ of N RI. It is natural to
[
construct a 95% conﬁdence interval for the N RI using N
RI ± 1.96 · Vb1 . However, a conﬁdence
interval constructed in this way is valid only if conditions (1), (2), and (3) in the previous paragraph
are true (or approximately true).
Pepe et al. (6) noted that Vˆ1 does not account for the variability of the ﬁtted model. That is,
when a risk model is ﬁt to a dataset, there is uncertainty in coeﬃcients of the model. This uncertainty
should be incorporated into inferences about summaries of prediction performance or the increment
of prediction. Vˆ1 ignores this uncertainty. Appendix E further elucidates problems with Vˆ1 as an
estimate of the variance of (N\
RI >0 ).
We conducted a simulation study to investigate whether conﬁdence intervals have the correct
coverage. We considered conﬁdence intervals constructed as described above. We also evaluated
[
[
[
[ [
conﬁdence intervals constructed using N
RI ± 1.96 · SE
B (N RI), where SEB (N RI) is a bootstrap
estimate of the standard error. Bootstrap estimates are obtained as follows. Re-sample rows of the
original dataset with replacement to construct a “bootstrap dataset” of the same size as the original
dataset. For a bootstrap dataset, re-ﬁt the “old” and “new” risk models and calculate the N RI
summary measures. Repeat this procedure a large number of times (e.g., 1000). This produces
a distribution of values for the summary measure called the bootstrap distribution. The standard
[
deviation of the bootstrap distribution is SE
B . Note that the bootstrap procedure incorporates the
[
variability of the ﬁtted model coeﬃcients into estimating SE(N
RI) because the risk model is re-ﬁt
on each bootstrap dataset.
Appendix C describes the simulation study. Table 1 gives the results for conﬁdence intervals
constructed using Vˆ1 and various bootstrap methods. Values in Table 1 should be compared to a
target value of 0.05. Conﬁdence intervals constructed using the formula for Vˆ1 have non-coverage
proportions substantially above or below the target value. Non-coverage proportions substantially
below 5% indicate conservative inference – conﬁdence intervals are wider than they should be. Noncoverage proportions above 5% indicate anti-conservative inference. With anti-conservative inference,
conﬁdence intervals are too narrow and one is falsely conﬁdent of the precision of results. The worst
0.1
>0
, with non-coverage proportions
and N RIne
performance was making conﬁdence intervals for N RIne
2-5 times as large as the target value.
[
Conﬁdence intervals constructed using SE
B show a clear tendency to give conservative results.
While conservative inference is not desirable, anti-conservative inference is not acceptable, particularly
at the levels we see in the tables for the formula for Vˆ1 .
The other bootstrap methods for constructing conﬁdence intervals did not work as as well as

7
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[
[
[
N
RI ± 1.96 · SE
B (N RI). We therefore recommend constructing conﬁdence intervals by using a
bootstrap estimate of the standard error of the statistic. Note that this method relies on approximate
[
Normality for N
RI. This is true asymptotically, but may not be a good assumption in small samples
or for weak biomarkers, especially for the 2-category NRI (7).
Table 1 gives results of our simulation study evaluating seven methods of forming conﬁdence
intervals. Data were simulated as described in Appendix C with µX = 0.74, r =0, and three values
for µY . We considered seven methods for constructing conﬁdence intervals.
√
[
1. N RI ± 1.96 · Vb1
[
[
[
2. N
RI ± 1.96 · SE
B (N RI). This is the same as 1 but uses resampling-subjects bootstrapping to
estimate the standard error.
3. Unadjusted. Uses resampling-subjects bootstrap but keeps the ﬁtted models ﬁxed.
4. Normal. This is similar to 2 but attempts to bias-correct the bootstrap estimate of the standard
error.
5. Basic
6. Percentile. Take the .025 and .975 quantiles of the bootstrap distribution of the statistic.
7. Bias-corrected and accelerated intervals.
The last four methods are described at
www.unc.edu/courses/2007spring/enst/562/001/docs/lectures/lecture28.htm.

8
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E

The Variance of Nd
RI

We simulated data as described in Supplement C. For all simulations we set the prevalence at 10%
(ρ = 0.1) and conditional independence (r = 0). We considered various values for the marginal
strength of the new marker Y , as indicated in the horizontal axis in the ﬁgures. We also considered
small, medium, and large samples sizes (300, 1000, and 10000). For each simulated dataset, we ﬁt the
logistic model, computed N RI >0 , and computed V̂1 . Across the 4000 simulations, we also computed
the empirical variance of N\
RI >0 . This resulted in a single empirical estimate of variance(N\
RI >0 ) to
compare to 4000 values of V̂1 .
Figure 2 shows some of the problems with using Vˆ1 to estimate the variance of N RI >0 . If the
incremental value of a marker is away from the null, Vˆ1 tends to underestimate the variance of N RI >0 .
Near the null, Vˆ1 tends to overestimate the variance of N RI >0 . This may be because of boundary
eﬀects as described in Demler et al. (1) for ∆AU C.
Sample Size =1000

1.4

1.4

Vˆ1 /SE(N RI >0 )

1.5

1.3

1.2

1.1

p

p

Vˆ1 /SE(N RI >0 )

Sample Size =300
1.5

1

0.9

0.8

1.3
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1

0.9

0
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µ
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0.5

0.65

0.8

0.8

0.95

0

0.05

0.1

y

0.15

0.25

µ
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Sample Size =10000
1.5

p

Vˆ1 /SE(N RI >0 )
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0.25

µ

0.35

0.5

0.65

0.8
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Figure 2: Vˆ1 as an estimate of the variance of N\
RI >0 . Results here are based on 4000 simulations for
each µY with ρ = 0.1 and r = 0. The sample
√ size of the simulated datasets is given over each set of
boxplots. The boxplots show the ratio of Vˆ1 divided by the empirical standard deviation across the
4000 simulations. Vˆ1 tends to overestimate the variance when the incremental value of the marker is
small and the sample size is small. For markers of modest incremental value and medium to larger
sample sizes, Vˆ1 tends to underestimate the standard error of N RI >0 .
9
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formula
[
SE
B
Unadjusted
Normal
Basic
Percentile
BCA

weak new marker (µY = 0.17)
>0
0.1
N RIe>0 N RIne
N RIe0.1 N RIne
0.009
0.135
0.134
0.091
0.012
0.035
0.004
0.004
0.006
0.134
0.206
0.101
0.074
0.141
0.096
0.059
0.098
0.162
0.087
0.066
0.009
0.024
0.001
0.002
0.066
0.132
0.142
0.097

formula
[
SE
B
Unadjusted
Normal
Basic
Percentile
BCA

medium new marker (µY = 0.34)
>0
0.1
N RIe>0 N RIne
N RIe0.1 N RIne
0.011
0.179
0.061
0.113
0.035
0.067
0.011
0.011
0.007
0.183
0.067
0.114
0.072
0.084
0.091
0.052
0.079
0.099
0.09
0.055
0.016
0.040
0.001
0.009
0.065
0.065
0.124
0.087

formula
[
SE
B
Unadjusted
Normal
Basic
Percentile
BCA

stronger new marker (µY = 0.74)
>0
0.1
N RIe>0 N RIne
N RIe0.1 N RIne
0.008
0.178
0.044
0.266
0.042
0.043
0.022
0.049
0.006
0.179
0.046
0.268
0.068
0.051
0.061
0.064
0.073
0.056
0.071
0.079
0.026
0.040
0.009
0.037
0.060
0.0423
0.074
0.067

Table 1: Non-coverage proportions for diﬀerent types of conﬁdence intervals. The method we recom[
mend is in the row labeled SE
B (it is called simply “bootstrap” in Table 3 in the article). Unadjusted,
Normal, Basic, Percentile, and BCA are various types of bootstrap conﬁdence intervals and are described in Appendix D.
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